Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30084147 | 1.00 | NPC1 (0.34) | NPC1MAPK14NAMPTMAPTCNR1 | |
| SCHEMBL3515098 | 0.90 | MAPT (0.42) | NPC1MAPTCNR1CNR2ACHE | |
| SCHEMBL16014236 | 0.87 | DGAT1 (0.34) | NPC1CNR1CNR2ACHEDGAT1 | |
| SCHEMBL29172496 | 0.87 | TBXAS1 (0.40) | NPC1MAPTCNR1CNR2ACHE | |
| SCHEMBL24809118 | 0.86 | DGAT1 (0.40) | NPC1MAPK14NAMPTMAPTDGAT1 | |
| SCHEMBL14493396 | 0.85 | MKNK1 (0.41) | NPC1MAPK14MAPT | |
| SCHEMBL24453181 | 0.82 | CNR1 (0.33) | NPC1CNR1CNR2ACHEDGAT1 | |
| SCHEMBL3515950 | 0.82 | L3MBTL1 (0.47) | NPC1MAPTCNR1CNR2ACHE | |
| SCHEMBL23782917 | 0.81 | IMPDH2 (0.39) | NPC1NAMPTCNR1CNR2ACHE | |
| SCHEMBL27615254 | 0.81 | PDE10A (0.36) | NPC1MAPTCNR1CNR2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022271840-A1 | SELECTIVE INDAZOLE LRRK2 INHIBITORS AND METHODS FOR USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20100298377-A1 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | disclosed |
| EP-2170865-A2 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF, AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009010660-A2 | SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF, AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298377-A1 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS | WEE1, PRMT1, ABL1 | NPC1 367/4885MAPK14 4667/4885NAMPT 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.